{"id":68035,"date":"2026-04-08T17:49:12","date_gmt":"2026-04-08T12:19:12","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=68035"},"modified":"2026-04-08T17:49:13","modified_gmt":"2026-04-08T12:19:13","slug":"glenmark-pharmaceuticals-q4-results-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/","title":{"rendered":"Glenmark Pharmaceuticals Q4 Results 2026: Date, Revenue, PAT &#038; Analyst Outlook"},"content":{"rendered":"<p>Glenmark Pharmaceuticals (NSE: GLENMARK) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With Glenmark Pharmaceuticals trading at Rs 1,300 \u2014 against a 52-week high of Rs 1,640 and a 1-year return of -12% \u2014 the Q4 FY26 results will be a pivotal event for investors.<\/p><p>Analyst estimates for Q4 FY26 revenue stand at Rs 3,850-4,100 Cr, with PAT expectations of Rs 350-400 Cr and margin projections of EBITDA 17-19%. This article covers the Glenmark Pharmaceuticals Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings and price targets, and answers to the most commonly searched investor questions.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Glenmark_Pharmaceuticals_Q4_Results_2026_Date\" title=\"Glenmark Pharmaceuticals Q4 Results 2026 Date\">Glenmark Pharmaceuticals Q4 Results 2026 Date<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Why_This_Quarter_Matters\" title=\"Why This Quarter Matters\">Why This Quarter Matters<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Glenmark_Pharmaceuticals_Q4_FY26_Earnings_Estimates\" title=\"Glenmark Pharmaceuticals Q4 FY26 Earnings Estimates\">Glenmark Pharmaceuticals Q4 FY26 Earnings Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#5_Key_Factors_That_Will_Drive_Glenmark_Pharmaceuticals_Q4_FY26_Performance\" title=\"5 Key Factors That Will Drive Glenmark Pharmaceuticals Q4 FY26 Performance\">5 Key Factors That Will Drive Glenmark Pharmaceuticals Q4 FY26 Performance<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Revenue_Momentum\" title=\"Revenue Momentum\">Revenue Momentum<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Margin_Trajectory\" title=\"Margin Trajectory\">Margin Trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#PAT_Quality\" title=\"PAT Quality\">PAT Quality<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Management_Guidance_for_FY27\" title=\"Management Guidance for FY27\">Management Guidance for FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Dividend_Declaration\" title=\"Dividend Declaration\">Dividend Declaration<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#5_Risks_to_Watch_in_Glenmark_Pharmaceuticals_Q4_FY26\" title=\"5 Risks to Watch in Glenmark Pharmaceuticals Q4 FY26\">5 Risks to Watch in Glenmark Pharmaceuticals Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#US_Tariff_and_Macro_Headwinds\" title=\"US Tariff and Macro Headwinds\">US Tariff and Macro Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Earnings_Miss_Risk\" title=\"Earnings Miss Risk\">Earnings Miss Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#FY27_Guidance_Below_Consensus\" title=\"FY27 Guidance Below Consensus\">FY27 Guidance Below Consensus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#FII_Outflow_Continuation\" title=\"FII Outflow Continuation\">FII Outflow Continuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Regulatory_Risk\" title=\"Regulatory Risk\">Regulatory Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Glenmark_Pharmaceuticals_Share_Price_and_Analyst_Ratings\" title=\"Glenmark Pharmaceuticals Share Price and Analyst Ratings\">Glenmark Pharmaceuticals Share Price and Analyst Ratings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#What_is_the_Glenmark_Pharmaceuticals_Q4_results_2026_date\" title=\"What is the Glenmark Pharmaceuticals Q4 results 2026 date?\">What is the Glenmark Pharmaceuticals Q4 results 2026 date?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#What_is_the_Glenmark_Pharmaceuticals_Q4_FY26_PAT_estimate\" title=\"What is the Glenmark Pharmaceuticals Q4 FY26 PAT estimate?\">What is the Glenmark Pharmaceuticals Q4 FY26 PAT estimate?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#What_is_Glenmark_Pharmaceuticalss_share_price_ahead_of_Q4_results\" title=\"What is Glenmark Pharmaceuticals&#8217;s share price ahead of Q4 results?\">What is Glenmark Pharmaceuticals&#8217;s share price ahead of Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Will_Glenmark_Pharmaceuticals_declare_a_dividend_in_Q4_FY26\" title=\"Will Glenmark Pharmaceuticals declare a dividend in Q4 FY26?\">Will Glenmark Pharmaceuticals declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Which_analysts_have_a_Buy_rating_on_Glenmark_Pharmaceuticals\" title=\"Which analysts have a Buy rating on Glenmark Pharmaceuticals?\">Which analysts have a Buy rating on Glenmark Pharmaceuticals?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#What_were_Glenmark_Pharmaceuticals_Q3_FY26_results\" title=\"What were Glenmark Pharmaceuticals Q3 FY26 results?\">What were Glenmark Pharmaceuticals Q3 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#When_do_Infosys_and_TCS_announce_Q4_results_2026\" title=\"When do Infosys and TCS announce Q4 results 2026?\">When do Infosys and TCS announce Q4 results 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Is_Glenmark_Pharmaceuticals_a_good_investment_ahead_of_Q4_results\" title=\"Is Glenmark Pharmaceuticals a good investment ahead of Q4 results?\">Is Glenmark Pharmaceuticals a good investment ahead of Q4 results?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q4-results-2026\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Glenmark_Pharmaceuticals_Q4_Results_2026_Date\"><\/span><strong>Glenmark Pharmaceuticals Q4 Results 2026 Date<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Get free investment predictions and live Q4 result alerts on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><p>Glenmark Pharmaceuticals has scheduled its Q4 FY26 results for May 2026 (Expected). Here is the broader Q4 FY26 earnings calendar context:<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Company<\/strong><\/td><td><strong>Date<\/strong><\/td><td><strong>Link<\/strong><\/td><\/tr><tr><td>TCS<\/td><td>April 9, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Infosys<\/td><td>April 23, 2026<\/td><td>Preview on Univest<\/td><\/tr><tr><td>Glenmark Pharmaceuticals<\/td><td>May 2026 (Expected)<\/td><td>This article<\/td><\/tr><\/tbody><\/table><\/figure><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Quarter_Matters\"><\/span><strong>Why This Quarter Matters<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Glenmark Pharmaceuticals enters Q4 FY26 with expectations of 10-14% YoY revenue growth. Q4 is the final quarter of the financial year \u2014 it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. At a 1-year return of -12%, this quarter&#8217;s results and FY27 guidance will be critical in determining whether the stock can begin a recovery.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Glenmark_Pharmaceuticals_Q4_FY26_Earnings_Estimates\"><\/span><strong>Glenmark Pharmaceuticals Q4 FY26 Earnings Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-320.jpeg\" alt=\"Glenmark Pharmaceuticals Q4 FY26 Earnings Estimates\" class=\"wp-image-68040\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-320.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-320-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-320-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-320-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-320-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-320-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p>Access premium SEBI-registered research on <a href=\"https:\/\/univest.in\/user\/log-in\">Univest<\/a>.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Metric<\/strong><\/td><td><strong>Q3 FY26 Actual<\/strong><\/td><td><strong>Q4 FY26 Estimate<\/strong><\/td><td><strong>Driver<\/strong><\/td><\/tr><tr><td>Revenue<\/td><td>Rs 3,684 Cr<\/td><td>Rs 3,850-4,100 Cr<\/td><td>Volume + pricing<\/td><\/tr><tr><td>PAT<\/td><td>Rs 320 Cr<\/td><td>Rs 350-400 Cr<\/td><td>Operating leverage<\/td><\/tr><tr><td>Margin<\/td><td>EBITDA 16.8%<\/td><td>EBITDA 17-19%<\/td><td>Cost control<\/td><\/tr><tr><td>Key Growth<\/td><td>&#8211;<\/td><td>10-14% YoY revenue growth<\/td><td>Management execution<\/td><\/tr><tr><td>Dividend<\/td><td>\u2014<\/td><td>Rs 5-8 per share<\/td><td>Board recommendation<\/td><\/tr><\/tbody><\/table><\/figure><p>Beyond headline numbers, investors will watch for FY27 guidance, margin trajectory, and order\/deal pipeline updates. A positive surprise on any two of these parameters could drive a meaningful post-results re-rating.<\/p><p>Screen <a href=\"https:\/\/univest.in\/screeners\">Glenmark Pharmaceuticals fundamentals<\/a> on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Key_Factors_That_Will_Drive_Glenmark_Pharmaceuticals_Q4_FY26_Performance\"><\/span><strong>5 Key Factors That Will Drive Glenmark Pharmaceuticals Q4 FY26 Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Revenue_Momentum\"><\/span><strong>Revenue Momentum<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts expect Rs 3,850-4,100 Cr in revenue for Q4 FY26 (Q3: Rs 3,684 Cr). Management&#8217;s ability to translate the order pipeline into recognised revenue will be the first test. Q4 is seasonally important for the Pharma sector, driven by year-end order execution and government capex push.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Margin_Trajectory\"><\/span><strong>Margin Trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Q4 FY26 margin expectations are EBITDA 17-19%, compared to EBITDA 16.8% in Q3. Input cost trends, employee expenses, and pricing power will determine the outcome. Any margin beat would be a significant positive catalyst given sector-wide cost pressure.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"PAT_Quality\"><\/span><strong>PAT Quality<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Net profit is estimated at Rs 350-400 Cr. Investors will assess whether PAT is driven by operational improvement or one-time items. A clean recurring profit print is more positively received than one inflated by non-operational gains.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Management_Guidance_for_FY27\"><\/span><strong>Management Guidance for FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The most consequential output from the Q4 FY26 announcement will be FY27 guidance \u2014 revenue growth bands, margin targets, capex plans, and macro risk commentary. Credible and specific guidance for FY27 will be valued highly by institutional investors.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dividend_Declaration\"><\/span><strong>Dividend Declaration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Glenmark Pharmaceuticals is expected to consider a final dividend of Rs 5-8 per share at the board meeting. The quantum signals confidence in free cash flow generation and sets expectations for FY27 capital allocation strategy.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Risks_to_Watch_in_Glenmark_Pharmaceuticals_Q4_FY26\"><\/span><strong>5 Risks to Watch in Glenmark Pharmaceuticals Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Tariff_and_Macro_Headwinds\"><\/span><strong>US Tariff and Macro Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The 26% US reciprocal tariff on Indian goods has created macro uncertainty affecting all Indian equities. For Glenmark Pharmaceuticals, indirect impacts include FII outflows and earnings estimate cuts if global demand slows. Tariff negotiation progress between India and the US remains the key macro wildcard.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Earnings_Miss_Risk\"><\/span><strong>Earnings Miss Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If Glenmark Pharmaceuticals&#8217;s Q4 FY26 results miss estimates, the stock could correct sharply \u2014 regardless of the longer-term fundamental story. Investors should monitor revenue versus the Rs 3,850-4,100 Cr estimate and PAT versus Rs 350-400 Cr as the two primary watchpoints on results day.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FY27_Guidance_Below_Consensus\"><\/span><strong>FY27 Guidance Below Consensus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>If management&#8217;s FY27 guidance for revenue or margins falls below Street expectations, the stock may decline even if Q4 numbers are in line. In the current macro environment, forward guidance carries more weight than the reported quarter.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FII_Outflow_Continuation\"><\/span><strong>FII Outflow Continuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>FIIs sold Rs 22,000 crore in Indian equities in one week following the tariff announcement. Continued selling pressure would create headwinds for Glenmark Pharmaceuticals regardless of company-specific fundamentals.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Regulatory_Risk\"><\/span><strong>Regulatory Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Pharma sector operates within evolving regulatory frameworks. Any policy changes that increase compliance costs or alter competitive dynamics could affect Glenmark Pharmaceuticals&#8217;s profitability beyond current consensus models.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Glenmark_Pharmaceuticals_Share_Price_and_Analyst_Ratings\"><\/span><strong>Glenmark Pharmaceuticals Share Price and Analyst Ratings<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"931\" height=\"486\" src=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-321.jpeg\" alt=\"Glenmark Pharmaceuticals Share Price and Analyst Ratings\" class=\"wp-image-68041\" srcset=\"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-321.jpeg 931w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-321-300x157.jpeg 300w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-321-768x401.jpeg 768w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-321-900x470.jpeg 900w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-321-600x313.jpeg 600w, https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-321-150x78.jpeg 150w\" sizes=\"(max-width: 931px) 100vw, 931px\" \/><\/figure><p>Glenmark Pharmaceuticals share price snapshot and analyst ratings. Source: Brokerages, NSE data.<\/p><p>Glenmark Pharmaceuticals is trading at Rs 1,300 as of early April 2026, against a 52-week high of Rs 1,640 and 52-week low of Rs 1,050. Market cap stands at Rs 36,800 Cr. The 1-year return of -12% reflects sector headwinds alongside company-specific factors.<\/p><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Brokerage<\/strong><\/td><td><strong>Rating<\/strong><\/td><td><strong>Target Price<\/strong><\/td><td><strong>Thesis<\/strong><\/td><\/tr><tr><td>MOFSL<\/td><td>Neutral<\/td><td>Rs 1,400<\/td><td>US generics; Ryaltris royalty<\/td><\/tr><tr><td>YES Securities<\/td><td>Buy<\/td><td>Rs 1,500<\/td><td>Respiratory franchise global<\/td><\/tr><tr><td>JM Financial<\/td><td>Add<\/td><td>Rs 1,420<\/td><td>India branded + US generic<\/td><\/tr><tr><td>Emkay<\/td><td>Buy<\/td><td>Rs 1,480<\/td><td>Ichnos biotech optionality<\/td><\/tr><\/tbody><\/table><\/figure><p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Glenmark Pharmaceuticals&#8217;s live price and receive real-time Q4 result alerts.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Glenmark Pharmaceuticals Q4 FY26 results on May 2026 (Expected) will be a key event for investors monitoring the Pharma sector. Analysts project PAT of Rs 350-400 Cr and revenue of Rs 3,850-4,100 Cr. At a CMP of Rs 1,300 with analyst targets ranging from Rs 1,480 to Rs 1,400, the stock offers risk-reward for informed investors. FY27 guidance will be the most critical post-results catalyst.<\/p><p>For more Q4 FY26 previews across sectors, visit <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Glenmark_Pharmaceuticals_Q4_results_2026_date\"><\/span><strong>What is the Glenmark Pharmaceuticals Q4 results 2026 date?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>The Glenmark Pharmaceuticals Q4 results 2026 date is May 2026 (Expected). The board of directors will meet to approve the audited Q4 FY26 financial results and consider a dividend recommendation for FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_the_Glenmark_Pharmaceuticals_Q4_FY26_PAT_estimate\"><\/span><strong>What is the Glenmark Pharmaceuticals Q4 FY26 PAT estimate?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Analysts estimate Glenmark Pharmaceuticals Q4 FY26 PAT in the range of Rs 350-400 Cr, based on revenue of Rs 3,850-4,100 Cr and margin of EBITDA 17-19%. Actual results may differ from consensus estimates.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_is_Glenmark_Pharmaceuticalss_share_price_ahead_of_Q4_results\"><\/span><strong>What is Glenmark Pharmaceuticals&#8217;s share price ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Glenmark Pharmaceuticals is trading at Rs 1,300 as of early April 2026. The 52-week high is Rs 1,640 and the 52-week low is Rs 1,050. The 1-year return is -12% and market cap is Rs 36,800 Cr.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Will_Glenmark_Pharmaceuticals_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Will Glenmark Pharmaceuticals declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Glenmark Pharmaceuticals is expected to consider a final dividend of Rs 5-8 per share at the Q4 FY26 board meeting on May 2026 (Expected), subject to board approval and AGM ratification.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Which_analysts_have_a_Buy_rating_on_Glenmark_Pharmaceuticals\"><\/span><strong>Which analysts have a Buy rating on Glenmark Pharmaceuticals?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>YES Securities (Buy, Rs 1,500), JM Financial (Add, Rs 1,420), Emkay (Buy, Rs 1,480) have positive ratings on Glenmark Pharmaceuticals heading into Q4 FY26.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_were_Glenmark_Pharmaceuticals_Q3_FY26_results\"><\/span><strong>What were Glenmark Pharmaceuticals Q3 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>Glenmark Pharmaceuticals reported Q3 FY26 revenue of Rs 3,684 Cr and PAT of Rs 320 Cr, with margin at EBITDA 16.8%. These form the baseline against which Q4 FY26 estimates are benchmarked.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"When_do_Infosys_and_TCS_announce_Q4_results_2026\"><\/span><strong>When do Infosys and TCS announce Q4 results 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>TCS declared Q4 FY26 results on April 9, 2026. Read the TCS Q4 Results 2026 preview on Univest Blogs. Infosys Q4 FY26 results are scheduled for April 23, 2026. Read the Infosys Q4 Results 2026 preview on Univest Blogs.<\/p><h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Is_Glenmark_Pharmaceuticals_a_good_investment_ahead_of_Q4_results\"><\/span><strong>Is Glenmark Pharmaceuticals a good investment ahead of Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3><p>This depends on your risk appetite, investment horizon, and portfolio context. Glenmark Pharmaceuticals has compelling long-term factors alongside genuine near-term risks. Consult a SEBI-registered financial advisor before making any investment decision. Use the Univest Screener to assess fundamentals independently.<\/p><p><strong>Disclaimer: <\/strong>Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE\/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/indian-oil-corporation-q4-results-2026\">Indian Oil Corporation Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/gujarat-gas-q4-results-2026\">Gujarat Gas Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/indus-towers-q4-results-2026\">Indus Towers Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/adani-total-gas-q4-results-2026\">Adani Total Gas Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/adani-enterprises-q4-results-2026\">Adani Enterprises Q4 Results 2026: Date, Revenue, PAT &amp; Analyst Outlook<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Glenmark Pharmaceuticals (NSE: GLENMARK) is preparing to announce its Q4 FY26 financial results for the period ended March 31, 2026. The board of directors is scheduled to meet on May 2026 (Expected) to approve the audited statements and consider a final dividend recommendation. With Glenmark Pharmaceuticals trading at Rs 1,300 \u2014 against a 52-week high<\/p>\n","protected":false},"author":28,"featured_media":68053,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3983],"class_list":["post-68035","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results-2026"],"metadata":{"_edit_lock":["1775652863:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"amazonS3_cache":["a:4:{s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-320.jpeg\";a:2:{s:2:\"id\";i:68040;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-320.jpeg\";a:2:{s:2:\"id\";i:68040;s:11:\"source_type\";s:13:\"media-library\";}s:62:\"\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/04\/image-321.jpeg\";a:2:{s:2:\"id\";i:68041;s:11:\"source_type\";s:13:\"media-library\";}s:94:\"\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174250\/image-321.jpeg\";a:2:{s:2:\"id\";i:68041;s:11:\"source_type\";s:13:\"media-library\";}}"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_description":["Glenmark Pharmaceuticals Q4 results May 2026 (Expected). PAT estimate Rs 350-400 Cr, margin EBITDA 17-19%. Full preview with analyst targets."],"rank_math_title":["Glenmark Pharmaceuticals Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_focus_keyword":["Glenmark Pharmaceuticals Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["68053"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["7560"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/08174740\/Glenmark-Pharmaceuticals.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68035","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=68035"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68035\/revisions"}],"predecessor-version":[{"id":68055,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/68035\/revisions\/68055"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/68053"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=68035"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=68035"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=68035"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}